Business Combination (Tables)

12 Months Ended

Dec. 31, 2015

Summary of Estimated Fair Values of Net Assets Acquired

The following table summarizes the values of the net assets acquired (in thousands):


	January 9, 2015
Inventory	$	52,676
Purchased intangibles		242,200
In-process research and development assets		20,900
Other assets		4,624
Goodwill		9,600
Total assets acquired		330,000
Other liabilities assumed		(5,000)
Total net assets acquired	$	325,000

Summary of Preliminary Fair Values Assigned to Assets Acquired and Amortization Period Assigned

The following is a summary of the fair values assigned to the assets acquired and the amortization period assigned to these rights (in thousands):


	December 31, 2015
			Estimated
	Gross		Useful
	Fair Value		Life
Generalized Lipodystrophy-United States	$	242,200	12
In-process research and development assets (1)		20,900	-
		263,100
Less accumulated amortization		(20,183)
Intangible assets, net	$	242,917

The in-process research and development assets include: partial lipodystrophy-U.S., GL and partial lipodystrophy-EU. These in-process research and development assets have been assigned indefinite lives and therefore will be tested for impairment annually on October 31 or in the event a triggering event presents itself.

Pro Forma Impact of Acquisition


	Year Ended
	December 31, 2014
	(in thousands)
Total net product sales	$	161,750
Net loss		(71,900)